Advertisement

Irish Journal of Medical Science

, Volume 180, Issue 1, pp 121–124 | Cite as

Proposed new approach for treating Paget’s disease of bone

  • W. Mahmood
  • M. J. McKenna
Original Article

Abstract

Background

Paget’s disease of the bone (PDB) is a localized disorder of bone remodeling. Nitrogen-containing bisphosphonates (N-BPs) are the treatment of choice.

Aim

We aimed to determine the effectiveness of N-BPs in our practice.

Methods

We prospectively tabulated clinical, imaging and biochemical data as well as interventions.

Results

All patients (n = 31) received one or more different N-BPs such as alendronate, risedronate, and zoledronic acid (ZA). Median (absolute range) serum total alkaline phosphatase (ALP) declined from 302 (55–1,600) to 69 (37–101) IU/L. In a subgroup of patients (n = 18) who received ZA after receiving an oral N-BP, median serum total ALP declined from 197 (44–1, 603) to 65 (37–95) IU/L.

Conclusions

Newly diagnosed patients with PDB should be treated for 6 months with oral N-BPs prior to administration of intravenous ZA. Repeat ZA infusions are necessary only if the serum total ALP levels rise above normal, or if symptoms or complications attributable to PDB persist.

Keywords

Paget’s disease of bone Bisphosphonates Zoledronic acid 

References

  1. 1.
    Siris ES, Roodman GD (2008) Paget’s disease of bone. In: Rosen CJ (ed) Primer on the metabolic bone disease and disorders of mineral metabolism. American Society of Bone and Mineral Research, Washington, pp 335–343CrossRefGoogle Scholar
  2. 2.
    Mangham DC, Davie MW, Grimer RJ (2009) Sarcoma arising in Paget’s disease of bone: declining incidence and increasing age at presentation. Bone 44:431–436CrossRefPubMedGoogle Scholar
  3. 3.
    Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2007) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759CrossRefGoogle Scholar
  4. 4.
    Reid IR, Miller P, Lyles K et al (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908CrossRefPubMedGoogle Scholar
  5. 5.
    Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH (2009) Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res 25:20–31CrossRefGoogle Scholar
  6. 6.
    Smith D, Murray BF, McDermott E, O′Shea D, McKenna MJ, McKenna TJ (2005) Hungry bones with hypocalcaemia following parathyroidectomy. J Bone Miner Metab 23:514–515CrossRefPubMedGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2010

Authors and Affiliations

  1. 1.St. Michaels HospitalDún LaoghaireIreland

Personalised recommendations